183 related articles for article (PubMed ID: 29432154)
1. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
[TBL] [Abstract][Full Text] [Related]
2. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
3. Moxetumomab Pasudotox: First Global Approval.
Dhillon S
Drugs; 2018 Nov; 78(16):1763-1767. PubMed ID: 30357593
[TBL] [Abstract][Full Text] [Related]
4. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
5. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
6. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
7. Domain II of
Müller F; Cunningham T; Beers R; Bera TK; Wayne AS; Pastan I
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29883379
[TBL] [Abstract][Full Text] [Related]
8. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
[TBL] [Abstract][Full Text] [Related]
10. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
11. Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.
Hu X; Wei H; Xiang L; Chertov O; Wayne AS; Bera TK; Pastan I
Leuk Res; 2013 Nov; 37(11):1551-6. PubMed ID: 24070652
[TBL] [Abstract][Full Text] [Related]
12. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN; Bhojwani D; August K; Baruchel A; Bertrand Y; Boklan J; Dalla-Pozza L; Dennis R; Hijiya N; Locatelli F; Martin PL; Mechinaud F; Moppett J; Rheingold SR; Schmitt C; Trippett TM; Liang M; Balic K; Li X; Vainshtein I; Yao NS; Pastan I; Wayne AS
Pediatr Blood Cancer; 2020 May; 67(5):e28112. PubMed ID: 31944549
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.
Müller F; Stookey S; Cunningham T; Pastan I
Oncotarget; 2017 May; 8(19):30644-30655. PubMed ID: 28423727
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Short NJ; Kantarjian H; Jabbour E; Cortes JE; Thomas DA; Rytting ME; Daver N; Alvarado Y; Konopleva M; Kebriaei P; Wierda WG; DiNardo CD; Bivins C; McCue D; Richie MA; Ravandi F
Br J Haematol; 2018 Aug; 182(3):442-444. PubMed ID: 28616864
[No Abstract] [Full Text] [Related]
15. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Karlin L; Robak T; Gladstone DE; le Coutre P; Dietrich S; Gotic M; Larratt L; Offner F; Schiller G; Swords R; Bacon L; Bocchia M; Bouabdallah K; Breems DA; Cortelezzi A; Dinner S; Doubek M; Gjertsen BT; Gobbi M; Hellmann A; Lepretre S; Maloisel F; Ravandi F; Rousselot P; Rummel M; Siddiqi T; Tadmor T; Troussard X; Yi CA; Saglio G; Roboz GJ; Balic K; Standifer N; He P; Marshall S; Wilson W; Pastan I; Yao NS; Giles F
Leukemia; 2018 Aug; 32(8):1768-1777. PubMed ID: 30030507
[TBL] [Abstract][Full Text] [Related]
16. Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
Kang C
Clin Drug Investig; 2021 Sep; 41(9):829-834. PubMed ID: 34383256
[TBL] [Abstract][Full Text] [Related]
17. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
18. [Moxetumomab pasudotox-Third line in Hairy cell leukemia].
Montes L; Herbaux C
Bull Cancer; 2021 Dec; 108(12):1073-1074. PubMed ID: 34776118
[No Abstract] [Full Text] [Related]
19. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; Fitzgerald DJ; Lechleider R; Pastan I
J Clin Oncol; 2012 May; 30(15):1822-8. PubMed ID: 22355053
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; FitzGerald DJ; Santiago L; Gao G; Lanasa MC; Pastan I
Blood; 2018 May; 131(21):2331-2334. PubMed ID: 29487070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
